- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Shilpa Medicare ink pact to sell 31 percent stake in Sravathi Advanced Process Technologies for Rs 49.6 crore

Karnataka: Shilpa Medicare Limited has announced that it has entered into a Share Purchase Agreement and Shareholders' Agreement with Ash Ingredients Inc. and Varcatalyst LLP to sell 31% of its stake held in Sravathi Advanced Process Technologies Pvt. Ltd. for a total consideration of Rs 49.6 crore, subject to customary closing conditions.
Following the transaction, Shilpa’s shareholding in Sravathi will reduce from 65% to 34%, while the technocrat founders will continue to hold 35%. Ash Ingredients Inc. and Varcatalyst LLP will hold 22% and 9% respectively.
As per the BSE filing, the transaction aims to bring in strategic and financial partners to bolster the business of Sravathi Technologies, a company engaged in advanced differentiated process technologies & research and development.
As part of the agreement, Ash Ingredients Inc. and Varcatalyst LLP have the right to appoint a director each on the Board of Sravathi.
Upon Closing of the transaction, the new agreements will supersede the earlier joint venture agreement dated June 7, 2019, between Shilpa, Technocrats, and Sravathi.
Shilpa Medicare is a global pharmaceutical company specializing in contract development and manufacturing services for small and large molecules. With a strong emphasis on oncology and a growing presence in biologics, the company offers comprehensive solutions from discovery to commercial supply. Shilpa Medicare operates R&D and manufacturing facilities, serving partners across North America, Europe, and Asia.
Read also: Shilpa Medicare gets initial authorization from EMA for Rivaroxaban Orodispersible Films
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

